Wound management technology projections

{Below is a summary of the products and technologies addressed in MedMarket Diligence report #S247, "Worldwide Wound Management, 2008-2017: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World."}

Wound management technologies are comprised of a remarkably diverse range of product types.  Dressings alone can be divided into multiple types, including film dressings, hydrocolloids, foam dressings, alginate dressings, hydrogels, non-adherent dressings, and antimicrobial dressings. Other wound products include cleansing and debridement products, tissue engineered products, pharmacological products, (including pain control, antibiotics, growth factors, non-growth factor modulators, gene therapy, and scarring modulators), physical treatments (like pressure devices, hydrotherapy, electrical stimulation, electromagnetic stimulation, ultraviolet therapy, hyperbaric oxygen therapy, mechanically assisted wound closure devices, ultrasound, laser and information systems. Some of these product categories are well established; others are in development.

Film Dressings. Film dressings are a vital segment of the advanced wound management market. The potential for film dressings in moist wound healing is a concept that is now over 20 years old. Due to the age of many of the strong brands in this segment, key patents on technologies and the delivery/application systems are expiring. This will erode premium prices, which have been maintained by creating new and differentiating application systems and the strong branding that is associated with them. Companies with strong know-how coupled with highly integrated low-cost manufacturing, and strong brand awareness will retain share in the marketplace.

Overall, despite increased competition and price pressure, this market segment will continue to demonstrate positive growth resulting from continued adoption of moist wound healing principles and switching from general non-occlusive dressings to advanced products such as films. The market for transparent film dressings is mature, and although individual products may provide a number of separate features, such as different moisture vapor transmission rates (MVTRs), they are purchased as commodities by buying groups. Given acceptable delivery systems, films compete on price. Global sales of film dressings are significant, but relatively stable, with price competition limiting sales growth to around 5% per year.

Hydrocolloid Dressings. The market for hydrocolloids grew rapidly in the 1980s and 1990s due to the products’ convenience and the fact that they can be left on some wounds for up to five days, together with widespread experience in their use, significant clinical support, and intensive marketing, that have helped grow sales volume over the years. Clinician customers developed a high awareness of these hydrocolloid brands and effectively substituted them for traditional fabric dressings once they had adopted the rationale for advanced wound care using moist wound healing. Major players in this segment of the market encouraged the use of hydrocolloids for all moist wound healing applications.

Hydrocolloids are used extensively in long-term care sites where wear time and ease of use are determining factors in dressing selection and in hospitals where they are popular with opinion leaders. However, hydrocolloids are now starting to lose ground in the face of competition from newer types of dressings with superior benefits. Sales of hydrocolloids are growing at a modest rate, but will nonetheless reach well over $1 billion by the year 2017. ConvaTec, Coloplast, and other strong players will find it increasingly difficult to defend these brands from advancing generic hydrocolloid equivalents produced by lower cost manufacturers with generic cost bases. In addition, there is a growing customer recognition that hydrocolloids have been superseded by other technologies (for example, foam dressings) for some wounds.

Foam Dressings. The ability to outperform hydrocolloids in highly exuding wounds, lack of dressing debris, and moderate cost have made foam dressings one of the fastest growing segments in the advanced wound care market. Foams are expected to maintain an aggressive market growth rate into the immediate future as these products take share from hydrocolloids due to their superior handling characteristics, and as they erode traditional gauze dressing usage. 

Alginate Dressings. Alginate dressings are popular in the home care and extended care markets where high absorption capacity is used to reduce the number and expense of skilled visits. In deeper wounds, alginates conform to the wound bed and contain exudates better than foam dressings. As with other advanced wound dressings, the alginate market is experiencing pricing pressure due to the continued cost consciousness of many individual country’s health care systems, and the generic nature of these materials and lack of proprietary intellectual property. Use of alginate dressings is especially common on moderate-to-highly exuding wounds. Alginates were quickly categorized as devices and reimbursed in the USA, UK, France and Germany, leading to strong growth in these countries. The relatively strong support for these products by expert wound care clinicians and the need for management of highly exudative wounds led to high sales growth in the mid 1990s. The alginate dressings market segment will grow at a healthy annual compound annual growth rate through 2017; in 2008, companies generated more than a half billion dollars from alginate dressings sales.

Hydrogels. Hydrogels are often promoted by referring to their aesthetic cooling effects, which help to reduce wound pain. Hydrogels are now perceived by clinicians as effective in encouraging autolytic debridement, and encouraging the healing of dry or minimally exuding wounds. Amorphous hydrogels and gauze-stabilized formats provide a real advantage in wound packing, and these products have been readily adopted by clinicians. In addition, hydrogels have good potential to serve as delivery systems for active agents. Competitors are actively introducing new hydrogel products to the market, and targeting alternate and home care markets. Thus, hydrogel sales are projected to grow at roughly 5% per annum from 2008 to 2017.

Approximately 50% of amorphous hydrogel products are used by clinicians to re-hydrate black necrosis or yellow slough for purposes of debridement. The other 50% of amorphous hydrogels are sold for use as a general hydration material for controlling moisture to aid moist wound healing.

Non-Adherent Dressings. Non-adherents are a vital part of the advanced wound management market. Products are used to permit less frequent changes of dressings and to allow the use of dressings that manage higher quantities of exudates but reduce the potential for these dressings to stick to the wound. They are also used in combination with traditional dressings as an alternative to more expensive advanced wound dressings. These dressings are also used as the primary contact layer for compression bandaging systems (although we have excluded sales due to this usage from our market estimates). Thus, non-adherent sales are projected to continue to grow at little better than 3% per annum through 2017.

Anti-Microbial Dressings. Anti-microbial dressings are used to manage the effects of microbial colonization and growth. Bacterial infection of wounds is a significant complication of wound repair. There is a growing concern regarding the use of antibiotic products in the wound care environment, and there are few “non-resistant-microbe-forming” antibiotic technologies on the horizon that offer potential to be launched within the next five years. In contrast to this, antimicrobial technologies are being pursued by all wound management companies, to enhance existing brands, and to address the recognized need in this area. Topical antiseptics are one option to treat patients with infected wounds; they act rapidly and locally to destroy microbes. Products fall into a number of categories, which tend to overlap with other categories of wound care products due to the product base technology used for the dressing category that inspired them. For example, Tulle Gras delivery systems have been used for some antibacterial products such as Inadine, Bactigras, and generic antibiotic impregnated products. Sales are projected to continue to grow at under 5% per annum from 2008 to 2017.

Wound Cleansers and Debriding Agents. The wound cleanser and debridement market is expected to grow at well over 5% annually, from over $400 million in 2010. The enzymatic debridement subsegment of this market is driven by the increase in the elderly population with the corresponding increase in nursing home populations and in-home health care environments where chronic wounds are prevalent. The increasing prevalence of diabetic ulcers contributes to the market potential for these agents.

Skin Replacements and Substitutes. Skin replacements and substitutes compete in the severe burn market, venous leg ulcers market, and the diabetic foot ulcer markets where their high cost is offset by their ability to save lives and/or save limbs from amputation. These products have taken some time to demonstrate clinical effectiveness and to be approved for use to heal wounds faster than alternative treatments. In addition, these products are currently significantly more expensive than alternative therapies, and publicly funded health care schemes around the world have found it difficult to accept these costs despite strong cost-effectiveness claims. It is highly likely that these products will take some time to be widely adopted. The move towards cost- effectiveness procurement practice is likely to increase uptake of these products as purchasers advance from decisions based on unit product cost towards outcomes assessments and data. In addition, manufacturers are developing alternative manufacturing and lower cost product designs that should enhance the cost effectiveness of these products over the next few years.

Pharmacological Products. In the field of wound management there are a large number of companies commercializing technologies in the pharmacological field. These technologies include recombinant growth factors and growth factor mixtures, gene therapy, chemical cell stimulants, natural plant extracts and other pharmaceuticals including analgesics, antibiotics, scar reduction products etc. Advanced wound care practices and dressings have focused on removal of the underlying cause of the wound, altering the physical environment, and provision of a moist wound healing environment. These efforts have greatly improved wound care by facilitating wound repair by supporting the body’s own repair and regenerative processes. Recent interest and efforts have been directed to evolving products and procedures designed to actively manipulate the wound healing process. In addition, antibiotics and analgesics have direct and beneficial application in the treatment of wounds in specific cases.

Physical Therapies. Physical modalities have been used in the attempt to encourage wound healing for centuries. Passive compression is a popular approach for the treatment of venous stasis ulcers and many of the current passive compression products have their roots in traditional practices (e.g., paste bandages). Passive compression addresses the underlying etiology of chronic venous insufficiency.

Alternatively there is a market for devices designed to remove pressure from wounds that have been caused by extended pressure on the skin surface, and this market segment has shown astronomical growth within the past 3-4 years, driven by the demonstrated ability of application of negative (i.e., sub-atmospheric) pressure to speed up and improve the healing of chronic wounds.

There are also a great number of devices that are designed to immobilize limbs to avoid weight-bearing behavior, and sophisticated footwear and devices for diagnosing neuropathy. In addition, devices exist to manipulate pressure around limbs to maintain and improve venous blood flow. There are devices designed to accelerate healing through the use of physical treatments including ultrasound, electrical, magnetic, hyperbaric, and pressure relief.

Taken together, these physicial treatment modalities commanded sales almost $2 billion in 2010 and annual growth at double digits for the period 2008–2017.

Tissue Engineered Products. Skin replacements are designed to replace missing skin, including the skin’s structures and biologic functions. Skin replacements may be from the patient’s own skin, from a human cadaver, or from an alternate species; or the skin replacement may be made from biomaterials or biodegradable synthetic materials with or without cells grown as tissue engineered constructs in culture. These tissue engineered products provide the matrix alone, epidermal tissue equivalent, dermal tissue equivalent, or a multi-layer human skin equivalent that includes both dermal and epidermal tissues. In addition this category includes some emergency burn cover products that are synthetic and biosynthetic dressings. These products have been used for some time as a temporary covering for severely burnt patients when insufficient graft material is available and the patient will otherwise die if the burns are not covered to reduce fluid loss and prevent infection. When skin for autografting is available, the temporary dressing is removed and graft is performed. This skin replacement category of products is receiving considerable R&D attention as biotechnology companies strive to develop replacement engineered skin to repair chronic wounds.


MedMarket Diligence report #S247:

The report details the current and projected market for wound management products, including dressings, closure devices, debridement, pharmacological products, tissue engineered products and others. Particular emphasis is placed on advanced and leading edge developments (i.e., those approaching wound management from novel perspective) such as growth factors, stem cells, gene therapy and other approaches, while baseline data (current and forecast market size and current competitor market shares) is provided for established segments — multiple dressings types (film, foam, alginate, antibacterial, non-adherent), hydrogels, hydrocolloids, pharmaceuticals, and physical treatments. The report details the clinical and technology developments underlying the huge and evolving worldwide wound care market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity. Separate size, growth and competitor data are presented for the U.S., leading western European countries, Japan and the Rest of World category. The report profiles leading and emerging companies, with data on products, technologies and positions in the advanced wound care market. The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Se also the related report $S180, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2015."

Obesity drug (and other treatments) market recalibrated

Despite a December advisory panel recommending Orexigen's Contrave for approval, the FDA this month reversed itself and rejected the combination drug, citing the need for long term safety and efficacy data and adding yet another blow to the obesity drug market — at least in the U.S.  Quick to declare the obesity drug market dead as a result, some market analysts have minimized (or ignored) the untapped demand for an effective obesity drug, the non-U.S. obesity drug markets that are, indeed, influenced by the U.S. FDA, but nonetheless free to operate of their own accord and readily do, and the number of obesity drugs still in the pipeline in the U.S. (including, potentially, Contrave among them).

Nonetheless, since we provided a comprehensive analysis of the obesity drug and device market in December, in which we recognized the challenges that other obesity drugs (e.g., lorcaserin, sibutramine, etc.) had encountered, but had crossed our fingers on the potential FDA approval of Contrave, the drug's FDA-tarnished U.S. prospects prompted us to revised our forecast of the balance of the obesity market across the range of treatment options:

  • Satiety Drugs
  • Malabsorption Drugs
  • Appetite Suppression Drugs
  • Combination Drugs
  • Restrictive Devices
  • Artificial Fullness Devices
  • Mal-absorption Devices
  • Gastric Emptying Devices
  • Appetite Suppression Devices

The MedMarket Diligence Report #S835, "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019", has been overhauled, with revised forecasts based on the recent market developments. The report is described in detail at this link and may be ordered online for immediate download or may be ordered via order form.

A $10 billion global medtech market for ablation technologies

The world market for energy-based ablation devices includes electrical, radiation, light, radiofrequency, ultrasound, cryotherapy, thermal, microwave and hydromechanical. 

The total market in 2009 was valued at nearly $10 billion. For the market period 2010-2019, the compound annual growth rate (CAGR) for the global market is projected to be 11.2%. The CAGR is deceptively modest, because these figures reflect the combined market sizes and growth rates of nine sectors. Those nine sectors, or modalities, vary widely in growth rates: from thermal, with an estimated CAGR (’09-’19) of under 3%, to cryotherapy with a CAGR of 19.5%. The energy-based ablation devices market is growing vigorously and will continue to grow at a strong rate during the study period.

(As defined in the MedMarket Diligence report #A145), the Americas consist of the USA, Canada, Mexico and Brazil; the European Union (EU) includes the United Kingdom, Germany, France, Spain, Italy and BeNeLux; Asia-Pacific represents Japan, China, India and Australia.

The different energy-based ablation segments vary widely in size, as shown in the following exhibit. Radiation accounted for one-third of the entire market in 2009, followed by light-based ablation (e.g., laser) with 19%. These two modalities accounted for 52% of the dollar value of the energy-based ablation device market in 2009. The CAGR (’10-’19) for radiation is about 8.1%; that of light is about 11%. 

Global Ablation Market Segments

Source: MedMarket Diligence, LLC, Report #A145, "Ablation Technologies Worldwide Market, 2009-2019: Products, Technologies, Markets, Companies and Opportunities".

Clinical Management of Obesity Worldwide

Publishing in November 2010:

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2009-2019

– 300 pages  – 95 Exhibits  – 54 Company Profiles  – February 2011  – Report #S835

Order online or via order form.
(Save $1,000 with advance price discount)

[This report description and table of contents is also available at report S835.]

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report profiles 60 of the leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Preliminary Table of Contents

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND OF OBESITY
1.1 Clinical Diagnosis of Obesity
1.1.1 Body Mass Index Scale
1.1.2 Measuring BMI vs. Measuring Adiposity
1.1.3 Classification of Obesity
1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity
1.1.5 Genetic Testing for Obesity
1.2 Obesogenic Influences
1.2.1 Dietary Changes Over the Last Twenty Years
1.2.2 Sedentary Lifestyles
1.2.3 Ongoing Research into Causes
1.3 Metabolic Pathways of Energy Homeostasis
1.3.1 Role of the Hypothalamus
1.3.2 Role of the Stomach
1.3.3 Role of the Small Intestine
1.3.4 Role of the Pancreas
1.3.5 Role of Adipose Tissue, An Endocrine Organ
1.3.6 Other Peptides
1.3.7 Obesity as Survival Mechanism
1.4 Co-Morbidities of Overweight and Obesity
1.4.1 Metabolic Syndrome
1.4.2 Effects of Obesity on Immune Function
1.4.3 Racial Differences in Co-morbidities
1.4.4 Type 2 Diabetes and Insulin Resistance
1.4.5 Hypertension
1.4.6 Dyslipidemia
1.4.7 Depression
1.4.8 Osteoarthritis
1.4.9 Asthma
1.4.10 Sleep apnea
1.4.11 Obesity and Cancer
1.5 Global Incidence and Prevalence of Obesity
1.5.1 By Geographic Region
1.5.1.1 USA, Canada, Mexico, Brazil
1.5.1.2 European Union
1.5.1.3 Asia-Pacific
1.5.2 By Age Group
1.5.2.1 Incidence and Prevalence among Children
1.5.2.2 Incidence and Prevalence among Elderly
1.5.3 Incidence and Prevalence of Morbid Obesity
SECTION 2: THE IMPACT OF OBESITY
2.1 Costs Related to Treating Obesity and Co-Morbidities
2.1.1 Current Healthcare Expenses
2.1.2 Breaking the Bank: Predictions of Future Healthcare Expenses
2.1.3 Healthcare Reform and Obesity
2.2 Impact on Businesses
2.2.1 Increased Health Insurance Costs
2.2.2 Increase in Workers’ Compensation Costs
2.2.3 Debate: Pay Employees to Lose Weight?
2.3 Legislating Prevention and Weight Loss
2.3.1 Changing Society: Educating Children as well as Adults
2.3.2 Pressure on the Food Industry
SECTION 3: CLINICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY
3.1 Role of Behavior Modification and Lifestyle Changes
3.1.1 Behavior Modification Programs: Decidedly Mixed Success
3.1.2 Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
3.1.3 Why Diets Usually Fail
3.2 Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
3.2.1 The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why
3.2.2 Drugs Currently on the Market
3.2.2.1 Appetite Suppression Drugs
3.2.2.2 Malabsorption Drugs
3.2.2.3 Satiety Drugs
3.2.2.4 Combination Drugs
3.2.3 Areas of Pharmaceutical Research
3.2.3.1 Melanocortin Receptor System
3.2.4 Drugs in the Pipeline—But Will They Hold Up?
3.2.4.1 Appetite Suppression Drugs
3.2.4.2 Malabsorption Drugs
3.2.4.3 Satiety Drugs
3.2.4.4 Combination Drugs
3.2.5 Safety: The Major Diet Drug Hurdle
3.2.6 After ‘Phen-Fen’ Experience, Will Physicians Prescribe Off-Label Combinations?
3.3 Non- Pharmaceutical Options for Treating Obesity
3.3.1 Permanent Surgical Modification
3.3.2 Surgical Revision of Bariatric Procedures
3.3.3 Short-Term Surgical/Device Solutions
3.3.4 Invasive Devices to Treat Obesity
3.3.4.1 Devices to Restrict Stomach Volume
3.3.4.2 Artificial Fullness Devices
3.3.4.3 Malabsorption Devices
3.3.4.4 Devices to Control Gastric Emptying
3.3.4.5 Appetite Suppressive Devices
SECTION 4: MARKET ASSESSMENT
4.1 Global Market for the Treatment of Obesity
4.1.1 Pharmaceuticals
4.1.1.1 Satiety
4.1.1.2 Malabsorption
4.1.1.3 Appetite Suppression
4.1.1.4 Combination Drugs
4.1.2 Devices
4.1.2.1 Stomach Restriction
4.1.2.2 Artificial Fullness
4.1.2.3 Malabsorption
4.1.2.4 Gastric Emptying
4.1.2.5 Appetite Suppression
4.2 Market Shares of Leading Companies
4.2.1 Leading Pharmaceutical Companies
4.2.2 Leading Device Companies
4.3 Americas Market for the Treatment of Obesity
4.3.1 USA
4.3.2 Canada
4.3.3 Mexico
4.3.4 Brazil
4.4 European Market for the Treatment of Obesity
4.4.1 United Kingdom
4.4.2 France
4.4.3 Germany
4.4.4 Italy
4.4.5 Spain
4.4.6 Rest of Europe
4.5 Asia-Pacific Markets for the Treatment of Obesity
4.5.1 Japan
4.5.2 India
4.5.3 China
4.5.4 Australia
4.5.5 Russia
4.6 ROW Markets for the Treatment of Obesity
4.7 Market Drivers and Restraints
4.7.1 Drivers
4.7.2 Restraints
4.8 Marketing Opportunities
SECTION 5: COMPANY PROFILES
5.1 Abbott Laboratories
5.2 Allergan
5.3 Amylin Pharmaceuticals
5.4 Arena Pharmaceuticals
5.5 AstraZeneca
5.6 BAROnova Therapeutics
5.7 BaroSense
5.8 Covidien
5.9 CR Bard, Inc.
5.10 Eli Lilly & Company
5.11 EndoGastric Solutions
5.12 EndoSphere
5.13 EndoVx
5.14 EnteroMedics
5.15 Ethicon Endo-Surgery (JNJ)
5.16 Gelesis, Inc.
5.17 GI Dynamics
5.18 GlaxoSmithKline
5.19 Helioscopie
5.20 Interleukin Genetics
5.21 IntraPace
5.22 Merck
5.23 Nestlé Healthcare Nutrition
5.24 NeuroSearch A/S
5.25 Novo Nordisk
5.26 Orexigen
5.27 Pfizer
5.28 ReShape Medical
5.29 Rhythm Pharmaceuticals
5.30 SafeStitch Medical, Inc.
5.31 Sanofi Aventis
5.32 Satiety
5.33 Scientific Intake, LLC
5.34 Silhouette Medical, Inc.
5.35 Spatz FGIA, Inc.
5.36 USGI Medical
5.37 ValenTx, Inc.
5.38 Verva Pharmaceuticals Ltd.
5.39 Vivus, Inc.
APPENDIX I: CLINICAL TRIALS
APPENDIX II: APPENDIX
Company Contact Details
Terms and Abbreviations Used in this Report

Surgical Sealants, Glues, Hemostasis, and Other Wound Closure Well Established Yet Still Growing Strong, According to New MedMarket Diligence Report

With its products filling many niches, established companies making acquisitions, startups still entering the market and clinical practice steadily adopting products in existing and new uses, the sealants, glues and related products markets reflect the characteristics of both well established and emerging technologies. A new report from MedMarket Diligence details the status and outlook for the products, technologies, companies and global markets.

Foothill Ranch, CA (PRWEB) October 28, 2010 — According to the newly released report, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015”, from MedMarket Diligence, the market for surgical closure and securement has entered a phase in which major driving forces are the introduction of new procedures and techniques by the surgical profession, the development by the medical device industry of new wound closure devices and biomaterials, and the growing willingness of surgical specialists to use these devices in appropriate circumstances. There is now a continuum between simple closure using sutures and the use of specially designed devices and delivery systems with new bioresorbable securement materials either as supplements to conventional closure methodology or as stand-alone replacements.

“There is a broad spectrum of activity in the ‘advanced wound closure’ or ‘securement’ market, with the characteristics of disruptive innovation of new technologies all the way through market consolidation and price erosion,” says Patrick Driscoll of MedMarket DIligence. “Surgical sealants, glues and related products are to some degree routine in clinical practice and to some degree still seeking to prove their utility in new applications, while traditional sutures, staples, clips, tapes and other products are struggling to maintain their competitiveness.”

Globally, the market has reached $10 billion for surgical sealants, glues, hemostasis, sutures, staples/clips, tapes and anti-adhesion products, with annual sales growth among the constituent segments ranging from 2.6% to in excess of 14% annually. The market continues to be characterized by the introduction of many new products, formation of new companies, growth of existing applications, and adoption of new applications. Simultaneously the market is evolving through consolidation and other dynamics typical of established markets.

The MedMarket Diligence report #S180, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015”, details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a market and technology assessment and forecast of surgical sealants, glues, hemostasis, other wound closure and anti-adhesion. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products, medical adhesives and products to prevent surgical adhesions. The report provides a worldwide historic (from 2008), current and annual forecast to 2015 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan, Korea and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a five-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

The MedMarket Diligence report, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2008-2015,” is described in detail, with a complete table of contents and list of exhibits at http://mediligence.com/rpt/rpt-s180.htm.

The report may be purchased for immediate download from http://mediligence.com/store/page41.html or may be purchased via order form at http://mediligence.com/order_forms/s180_order.pdf.

MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.

Surgical securement market, Latin America

The securement market, encompassing fibrin sealants/glues, high strength glues (cyanoacrylates, others), hemostatic agents, sutures, staples, other mechanical closure and products for the prevention of post-surgical adhesion, in most segments reflects an advanced wound technologies market.  As is the cast with virtually all medtech markets, the dominant geographies driving securement revenues are the U.S., Europe and Asian countries like Japan and Korea.  However, considerable attention is being given to Latin America, based on the level of healthcare market development, the population and potential caseload, and the relative ease of distribution, particularly for U.S.-based manufacturers (although, not to overstate the opportunity, since by comparison to the well established western markets, Latin America is clearly less driven by high healthcare expenditure and utilization of advanced technologies).

By capitalizing on existing distribution networks, trade agreements and the simple proximity of geography for major U.S. manufacturers, the opportunity of Latin America has been a profitable consideration.

Source: MedMarket Diligence, LLC; report #S180.

Report: Surgical Sealants, Glues, Wound Closure and Anti-adhesion Worldwide

MedMarket Diligence (MMD) has published its 2010 report on the worldwide market for surgical sealants and related products in surgical and traumatic wound management.

The analysis by MMD reveals the size of the evolving opportunity for a diverse set of products in global markets. Based on extensive primary and secondary research, and leveraging MMD’s position as the leading source for the medtech industry on the subject, the report provides industry participants and hopefuls with invaluable data and insights.

The report is described below and at link

This report details the complete range of sealants & glues technologies used in traumatic, surgical and other wound closure, from tapes, sutures and staples to hemostats, fibrin sealants/glues and medical adhesives. The report details current clinical and technology developments in this huge and rapidly growing worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.

This report is a market and technology assessment and forecast of surgical sealants, glues, hemostasis, other wound closure and anti-adhesion. The report details the current and emerging products, technologies and markets involved in wound closure and sealing using sutures and staples, tapes, hemostats, fibrin and sealant products, medical adhesives and products to prevent surgical adhesions. The report provides a worldwide historic (from 2008), current and annual forecast to 2015 of the markets for these technologies, with particular emphasis on the market impact of new technologies through the coming decade.  The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan, Korea and Rest of World.

The report provides background data on the surgical, disease and traumatic wound patient populations targeted by current technologies and those under development, and the current clinical practices in the management of these patients, including the dynamics among the various clinical specialties or subspecialties vying for patient population and facilitating or limiting the growth of technologies.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a five-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

See link for complete table of contents and list of exhibits.  The report may be ordered for immediate download from link.

The growing need for diabetes management globally

Population growth, trends in obesity prevalence, economic drivers and other forces are creating an enormous need for products in the management of diabetes.  In the aggregate, over the next twenty years, the prevalence of diabetes in the adult population (age 20-79) will increase from 285 million worldwide in 2010 to 438 million in 2030, an overall increase of 54%.

NAC: North America and Caribbean region; MENA: Middle East and North Africa region; SEA: South East Asia region; EUR: European region; SACA: South and Central America region; WP: Western Pacific region; AFR: Africa region.

Source: IDF Diabetes Atlas and MedMarket Diligence, LLC.

 

The greatest number of newly diagnosed diabetes mellitus patients are arising in South East Asia (SEA), Western Pacific (WP) and Middle East and North Africa (MENA), as illustrated below (figures in millions):

Source: IDF Diabetes Atlas and MedMarket Diligence, LLC.

 

Growth of the diabetes patient population in North America and Europe, with its well developed economies and healthcare system infrastructure, is occurring at a compound annual growth rate, from 2010 to 2030, of 1.8% in North America and 0.9% in Europe. These new patients will be readily integrated into the existing infrastructure of clinical management.  By contrast, however, the large numbers of patients arising from South East Asia, the Western Pacific and the Middle East and North Africa will demand development of infrastructure to manage these patients and supply the appropriate diagnostic and therapeutic products for management of their diabetes mellitus.


Data is drawn from the International Diabetes Federation and MedMarket Diligence Report #D510, "Worldwide Diabetes Management."

Sealants, glues, wound closure, anti-adhesion market segments by country

The global market for surgical sealants, glues, other wound closure and anti-adhesion products (collectively referred to as "securement "products) is, like many medtech markets, dominated by the U.S., followed by Europe.  But as one examines the performance of individual product segments in this market, it becomes clear that local markets have enough differences in their drivers to result in surprising variation from one another.

Below are illustrated the absolute size of the markets for products in securement by country and the relative contribution of revenues from each securement product type by country.  The differences stand out.

Source: Preliminary findings, Report #S180, "Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2015". (Publishing October 2010)

Latin American markets for surgical sealants, glues, hemostasis and ant-adhesion products

MedMarket Diligence's worldwide analysis of the markets for surgical sealants, glues, hemostasis, wound closure and anti-adhesion provides detail on growth segments of the market, both in the products/technologies and the geographic breakdown.  Below is an excerpt from Report #S175.


The main medical markets in Latin America are Brazil and Mexico, followed by Argentina.

Brazil, despite its size (population 196 million), is not a lucrative medical market because of the wide economic disparity between the wealthy and poor segments of the population. The state-run Unified Health System (SUS) covers 75% of the population but only 42% of total health care expenditure is in the public sector. Private health care covers 17.5 million subscribers, less than 10% of the population. Thus conventional, low-cost closures (sutures, staples, tapes) dominate the market and more expensive novel closures (sealants and glues) have relatively modest market shares. The same is true of Argentina, which is still recovering from a severe economic depression in the 1990s. Mexico, the eighth biggest trading market in the world, operates a health care system under which 60%–70% of the population are covered by public insurance schemes. In terms of expenditure on medical products, Mexico occupies a position between that of developed and developing economies, and this is reflected in the shares of the wound closure market represented by premium-priced and commodity product groups.

[ad#ad-1]

Below is shown a graph of the major Latin American markets for these products.  As is shown, sealants and glues have gained a significant share of these markets, yet additional penetration of the sutures and staples segment by sealants/glues, potentially to a large degree, may be gained with additional product development, conversion of caseload and aggressive marketing/promotional campaigns to physicians in these markets.

latin-america2

Source: MedMarket Diligence, LLC; Report #S175